E-News - May 2020

2020 Virtual ASCO MEETING May 29-31

The 56th Annual Meeting of the American Society of Clinical Oncology (ASCO) will convene virtually May 29-31. The ASCO meeting brings together oncology professionals from around the world. This year's meeting theme is "Unite and Conquer: Accelerating Progress Together." Studies spanning the spectrum of cancer prevention and care, from immunotherapy and precision medicine to survivorship, will be highlighted.  

Each year, ASCO attendees learn from leading-edge scientific presentations, including papers and talks from Alliance researchers, as well as thousands of scientific abstracts and research news developments. At this year's conference, Alliance investigators will present more than 20 studies, sharing the latest findings on breast cancer, head and neck cancer, lung cancer, GI and GU cancers, along with cancer control research. The Alliance will be well-represented with researchers participating on panels, discussing new research and presenting posters.
Join the Twitter conversation at #ASCO20 and please include @ALLIANCE_org
Here's a snapshot of studies that Alliance researchers will be presenting:

Breast Cancer - Local/Regional/Adjuvant      
ALTERNATE: Neoadjuvant endocrine treatment (NET) approaches for clinical stage II or III estrogen receptor-positive HER2-negative breast cancer (ER+ HER2- BC) in postmenopausal (PM) women: Alliance A011106
Lead author: Cynthia X. Ma
Abstract: 504
Clinical trial information: NCT01953588
Value of CTS5 for Late Relapse Risk Assessment in Patients with Early Stage HER2+ Breast Cancer in the NCCTG N9831 (Alliance) Trial
Lead author: Tanmayi Pai
Abstract/Poster: 529 / 21    
Clinical trial information: NCT00005970
Cancer Prevention, Risk Reduction, and Genetics   
Association of CEP72 rs924607 with vincristine-induced peripheral neuropathy in patients with diffuse large B-cell lymphoma on Alliance/CALGB 50303
Lead author: Daniel
L. Hertz        
Abstract: E13535
Central Nervous System
Alliance A071401: Phase II trial of FAK inhibition in meningiomas with somatic NF2 mutations
Lead author: Priscilla K. Brastianos        
Abstract: 2502         
Clinical trial information: NCT02523014
Alliance A071701: Genomically guided treatment trial in brain metastases
Lead author: Priscilla Brastianos
Abstract/Poster: TPS2573 / 64     
Clinical trial information: NCT03994796
Developmental Therapeutics - Immunotherapy       
A151804, 9767        
Alliance A151804: Establishment of a national biorepository to advance studies of immune-related adverse events
Lead author: David Kozono         
Abstract/Poster: TPS3154 / 218   
Clinical trial information: NCT04242095
Gastrointestinal Cancer - Colorectal and Anal         
Predictive and prognostic value of HER2 gene expression and HER2 amplification in patients with metastatic colorectal cancer (mCRC) enrolled in CALGB/SWOG 80405 (Alliance)
Lead author: Francesca Battaglin           
Abstract/Poster: 4086 / 78
Clinical trial information: NCT00265850
C80405, N9741      
Rural and urban disparities based on zip code of residence: Analyses of 834 and 2159 patients in NCCTG N9741 and CALGB 80405 (Alliance) trials respectively
Lead author: Midhun Malla          
Abstract: E16076    
Clinical trial information: NCT00003594 NCT00265850

Celecoxib in addition to standard adjuvant therapy with 5-fluorouracil, leucovorin, oxaliplatin (FOLFOX) in stage III colon cancer: Results from CALGB/SWOG 80702
Lead author: Jeffrey A. Meyerhardt         
Abstract: 4003         
Clinical trial information: NCT01150045
Tumor infiltrating lymphocytes and tumor budding refine prognostication in patients with low and high risk stage III colon cancers (NCCTG N0147) [Alliance]
Lead author: D. Sha           
Abstract/Poster: 4065 / 57
Overall survival (OS) and long-term disease-free survival (DFS) of three versus six months of adjuvant (adj) oxaliplatin and fluoropyrimidine-based therapy for patients (pts) with stage III colon cancer (CC): Final results from the IDEA (International Duration Evaluation of Adj chemotherapy) collaboration
Lead author: Alberto F. Sobrero  
Abstract: 4004          
Clinical trial information: NCT01150045
Genitourinary Cancer - Kidney and Bladder
PDIGREE: An adaptive phase 3 trial of PD-inhibitor nivolumab and Ipilimumab (IPI-NIVO) with VEGF TKI cabozantinib (CABO) in metastatic untreated renal cell cancer (Alliance A031704)
Lead author: Tian Zhang  
Abstract/Poster: TPS5100 / 169   
Clinical trial information: NCT03793166
Health Services Research and Quality Improvement        
Nurse, oncologist, and patient impressions of electronic symptom monitoring via patient-reported outcomes in community oncology practices: Qualitative results from the U.S. national PRO-TECT trial
Lead author: Ethan Basch
Abstract/Poster: 7044 / 316          
Clinical trial information: NCT03249090
A151925, A091105, COMET-2    
Composite grading algorithm for National Cancer Institute's PRO-CTCAE
Lead author: Amylou C. Dueck
Abstract/Poster: 7018 / 290
Hematologic Malignancies - Lymphoma and Chronic Lymphocytic Leukemia           
Myeloablative versus non-myeloablative consolidative chemotherapy for newly diagnosed primary central nervous system lymphoma: Results of induction therapy in Alliance 51101
Lead author: Tracy Batchelor       
Abstract/Poster: 8042 / 375          
Clinical trial information: NCT01511562
Toxicity burden in older patients with chronic lymphocytic leukemia (CLL) receiving bendamustine with rituximab (BR) or ibrutinib (IB) regimens: Alliance A041202
Lead author: Amy S. Ruppert       
Abstract: E20004    
Clinical trial information: NCT01886872
A051103, C50701, C50801, C50901, S0016, S0816
Relevance of bone marrow biopsies for response assessment in NCTN follicular lymphoma clinical trials
Lead author: Sarah C. Rutherford           
Abstract/Poster: 8038 / 371          
Clinical trial information:  NCT00553501 NCT01145495 NCT01190449 NCT01286272 NCT01829568 NCT00822120 NCT00770224

Non-Small Cell Local/Regional/Small Cell/Other Thoracic Cancers       
AFT-16: Phase II trial of atezolizumab before and after definitive chemoradiation for unresectable stage III NSCLC
Lead author: Helen J. Ross          
Abstract/Poster: 9045 / 238          
Clinical trial information: NCT03102242
A081105, A151216, A081801     
ALCHEMIST: Adjuvant targeted therapy or immunotherapy for high risk resected NSCLC (Alliance)
Lead author: Jacob Sands
Abstract/Poster: TPS9077 / 270   
Clinical trial information: NCT02194738
A multicenter phase II study of nivolumab +/- ipilimumab for patients with metastatic sarcoma (Alliance A091401): Results of expansion cohorts
Lead author: James Chen
Abstract/Poster: 11511 /399         
Clinical trial information: NCT02500797

A randomized phase II study of MLN0128 (M) versus pazopanib (P) in patients (pt) with advanced sarcoma (Alliance A091304)
Lead author: Matthew Ingham     
Abstract/Poster: 11562 / 450        
Clinical trial information: NCT02601209
Symptoms and Survivorship     
A pilot randomized, placebo-controlled, double-blind study of omega-3 fatty acids to prevent paclitaxel-associated acute pain syndrome
Lead author: Zoneddy Dayao      
Abstract: E24115    
Clinical trial information: NCT01821833     
Randomized trial of a symptom monitoring intervention for hospitalized patients with advanced cancer. (NCT03396510)
Lead author: Ryan D. Nipp           
Abstract/Poster: 12014 / 302        
Clinical trial information: NCT03396510
A phase III randomized, double-blind placebo controlled study of armodafinil (nuvigil®) to reduce cancer-related fatigue in patients with high grade glioma (Alliance A221101)
Lead author: Alyx B. Porter           
Abstract: 12007       
Clinical trial information: NCT01781468
Decision aids for localized prostate cancer: Outcomes from an Alliance Research Base Cancer Care Delivery Research (CCDR) protocol - A191402CD
Lead author: Jon Tilburt    
Abstract: e24176    
Clinical trial information: NCT03103321